PATENT CLAIM ANALYSIS

Application Number: 15920885
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-09
Patent Classification: ["514", "035000"]

Abstract:
Embodiments disclosed herein provide compositions and methods for treating lymphangioleiomyomatosis (LAM) comprising inhibiting COX overexpression and prostaglandin over production by administering at least one COX inhibitor and/or prostaglandin biosynthetic pathway inhibitors.

Claim (Index 60):
The composition of  claim 1 , further comprising rapamycin, and at least one compound selected from the group consisting of SCH-202676 hydrobromide, danusertib (PHA-739358), AZ-960, nicardipine, SB-590885, Thimerosal, ionomycin, U-73343, PAF C16, BX912, and Chlorambucil.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 90.0
- Lexical Diversity: 1.09677
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14771817', '15305883', '12989529', '13520472', '10639263']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7601013752718545
- 35 USC 102 Novelty (BERT): 0.6361136513013809
- Combined Prediction Score: 0.7477026028748072
- Mean Citation Score: 362.809348
- Max Citation Score: 751.68854
- Similarity Product: 530.8648069321669

Labels:
- Claim Label 101: 0
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test